Diltiazem Treatment for Preclinical Hypertrophic Cardiomyopathy Mutation Carriers: A Pilot Randomized Trial to Modify Disease Expression

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is caused by sarcomere mutations and characterized by left ventricular hypertrophy (LVH) with increased risk of heart failure and sudden death. HCM typically cannot be diagnosed early in life, although subtle phenotypes are present. Animal studies indica...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JACC Heart Fail
Autori principali: Ho, Carolyn Y., Lakdawala, Neal K., Cirino, Allison L., Lipshultz, Steven E., Sparks, Elizabeth, Abbasi, Siddique A., Kwong, Raymond Y., Antman, Elliott M., Semsarian, Christopher, González, Arantxa, López, Begoña, Diez, Javier, Orav, E. John, Colan, Steven D., Seidman, Christine E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323670/
https://ncbi.nlm.nih.gov/pubmed/25543971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jchf.2014.08.003
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi